Opko Health's CEO Phillip Frost buys $169,712 in stock

Published 10/04/2025, 22:10
Opko Health's CEO Phillip Frost buys $169,712 in stock

Phillip Frost, CEO and Chairman of OPKO Health Inc. (NASDAQ:OPK), has acquired a significant amount of the company's common stock. According to a recent SEC filing, Frost purchased 125,000 shares on April 10, 2025, at a weighted average price of approximately $1.3577 per share, resulting in a total transaction value of $169,712. The purchase comes as InvestingPro data shows the stock trading near its Fair Value, with shares down 5% in the past week despite maintaining a healthy current ratio of 3.43x.

The shares were acquired indirectly through Frost Gamma Investments Trust, where Frost serves as trustee. Following this transaction, Frost's indirect ownership in OPKO Health stands at 214,001,448 shares. Additionally, he holds 3,568,951 shares directly and 30,127,177 shares indirectly through other entities. InvestingPro analysis reveals management's continued share purchases as a positive signal, with 8 additional exclusive ProTips available for subscribers looking to make informed investment decisions about OPK's $910M market cap healthcare company.

In other recent news, Opko Health reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $0.01, against a forecasted loss of $0.08. However, the company's revenue of $103.1 million fell short of the anticipated $156.35 million. In a strategic move, Opko Health announced a significant transaction with Labcorp, selling laboratory testing businesses for $192.5 million, with an additional earn-out of up to $32.5 million. Additionally, Opko Health expanded its stock repurchase program to $200 million, reflecting confidence in its business strategy. H.C. Wainwright maintained a Buy rating on Opko Health, with a price target of $3.00, highlighting the company's proactive measures to increase shareholder value. Opko Health also entered into a collaboration with Entera Bio (NASDAQ:ENTX) to develop an oral treatment for obesity, holding a 60% ownership interest in the partnership. The companies plan to submit an Investigational New Drug application to the FDA later this year. Despite the revenue miss, Opko Health remains optimistic about its future, projecting total revenue between $675 million and $700 million for 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.